Our findings in patients after bevacizumab therapy support the concept that VEGF inhibition leads to hyperproliferative endothelial cells that occlude the pulmonary vascular lumen, an observation that has been labeled as “the angiogenesis paradox in pulmonary arterial hypertension” [51]. This evidence concerns the gene VEGFA and pulmonary arterial hypertension.